Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man

Neuroscience Letters

Volumn 195, Issue 2, 1995, Pages 137-139

  Kornhuber, J ^a   Quack, G ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

CSF level; Dementia syndromes; Glutamate; Human; Memantine; NMDA receptor; Pharmacokinetics; Serum level

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AGED; DEMENTIA; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MIDDLE AGED; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0029085113     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3940(95)11785-U     Document Type: Article

References (19)

1. Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels
2. Open-channel block of N-methyl-d-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity
3. Are NMDA antagonistic properties relevant for anparkinsonian-like activity in rats? — case of amantadine and memantine
4. Efficacy and tolerability of memantine in patients with dementia syndrome
5. Memantine in the treatment of mild to moderate dementia syndrome: a double-blind placebocontrolled study
6. Memantin und neurogene Blasenstörungen im Rahmen spastischer Zustandsbilder
7. Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and β-adrenergic transmission
8. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion chanel: a human postmortem brain study
9. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex
10. Therapeutic brain concentration of the NMDA receptor antagonist amantadine.
11. Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists
12. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
13. Learning deficits induced by chronic intraventricular infusion of quinolineacid; protective effects of subcutaneous infusions of MK-801 and memantine
14. Erfahrungen mit Memantine bei der Behandlung schwerer spastischer und extrapyramidaler Bewegungstörungen in Kombination mit der stereotaktischen Operation
15. Patch clamp studies on the kinetic and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
16. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease
17. Wirkungen oraler Memantin-Gaben auf die Parkinson-Symptomatik
18. Memantine-induced dopamine release in the prefrontal cortex and striatum of the rat: a pharmacokinetic microdialysis study
19. Distribution and metabolism of the potential anti-parkinson drug memantine in the human